Turn Therapeutics (TTRX) investor relations material

Executive summary

• Developing GX-03, a first-in-class, non-systemic immunomodulator targeting IL-36 and key cytokines for inflammatory skin diseases, initially focusing on moderate to severe atopic dermatitis (AD).

• Over 200,000 patients have received GX-03 with zero reported adverse events in other FDA-cleared indications.

• Robust intellectual property portfolio with issued patents for composition and methods, supporting commercial exclusivity.

• Phase 2 randomized controlled trial for moderate to severe AD is underway, with topline results expected in Q4 2026.

• FDA clearances for non-cytotoxic, non-sensitizing, and non-irritating claims.

Technology platform

• PermaFusion is a patented, API-agnostic drug delivery platform enabling stable, emulsifier-free dispersion of active ingredients in oil-based carriers.

• Allows delivery of nanodroplets through skin, nails, and mucous membranes, compatible with any liquid or liquid-soluble API, including live payloads.

• Multi-step mixing process without emulsifiers enhances penetration and stability.

Clinical pipeline and milestones

• GX-03 is in Phase 2 for moderate to severe AD, with Phase 3 initiation planned for mid-2027 and potential commercial launch by 2029.

• Phase 3-ready for onychomycosis, with a pivotal trial planned for 2027 and commercial launch by 2029.

• Preclinical stage for hidradenitis suppurativa (HS), with a Phase 2a trial planned for 2027.

• Out-licensed medical devices generating milestone payments.